首页 | 本学科首页   官方微博 | 高级检索  
检索        

分化型甲状腺癌131I治疗的动态评估及影响最佳疗效反应的因素分析
引用本文:任丽,黄凯,胡永全,范念念,邹明远,孙俊杰,袁超,李玉云.分化型甲状腺癌131I治疗的动态评估及影响最佳疗效反应的因素分析[J].蚌埠医学院学报,2022,47(2):165-168, 172.
作者姓名:任丽  黄凯  胡永全  范念念  邹明远  孙俊杰  袁超  李玉云
作者单位:1.蚌埠医学院 检验医学院, 安徽 蚌埠 2330302.苏州大学 放射医学与辐射防护国家重点实验室, 江苏 苏州 2151233.苏州大学医学部 放射医学与防护学院, 江苏 苏州 2151234.蚌埠医学院第一附属医院 核医学科, 安徽 蚌埠 2330045.蚌埠医学院 临床医学院, 安徽 蚌埠 233030
基金项目:国家级大学生创新训练项目(202110367067);;安徽省教育厅自然科学研究重点项目(KJ2016A466,KJ2020A0581,KJ2021A0712);
摘    要:目的分析影响非远处转移分化型甲状腺癌(DTC)病人术后131I治疗后获得最佳治疗(ER)的因素。方法纳入131I治疗后随访满24个月的病人160例,动态评估其治疗后3、6、12及24个月疗效反应。采用χ2检验、Fisher精确检验和Mann-Whitney U秩和检验分析不同疗效分层病人临床病理差异,应用logistic回归分析和ROC曲线分析探究影响病人最佳疗效反应的因素。结果与初始评估时相比,终末评估时ER明显升高(P < 0.01);而ER组年龄小、ps-Tg水平较低、131I治疗次数 < 3次、131I治疗总剂量 < 500 mCi、初始危险分层低危及初始TNM分期Ⅰ~Ⅱ期的病人比例均高于非ER组(P < 0.05~P < 0.01)。血清ps-Tg是影响终末期ER的保护因素(OR=0.942,P < 0.01)。ps-Tg与初始及终末ER关系的ROC曲线下面积分别为0.884、0.762,预测非ER的最佳临界值为16.62 ng/mL和46.37 ng/mL(P < 0.01)。结论131I治疗非远处转移DTC疗效显著,血清ps-Tg对预测初始评估和终末评估疗效的具有重要价值。

关 键 词:分化型甲状腺癌    131I治疗    动态评估    最佳治疗反应
收稿时间:2021-03-12

Dynamic evaluation of 131I therapy for differentiated thyroid carcinoma and analysis of factors influencing the excellent response
REN Li,HUANG Kai,HU Yong-quan,FAN Nian-nian,ZOU Ming-yuan,SUN Jun-jie,YUAN Chao,LI Yu-yun.Dynamic evaluation of 131I therapy for differentiated thyroid carcinoma and analysis of factors influencing the excellent response[J].Journal of Bengbu Medical College,2022,47(2):165-168, 172.
Authors:REN Li  HUANG Kai  HU Yong-quan  FAN Nian-nian  ZOU Ming-yuan  SUN Jun-jie  YUAN Chao  LI Yu-yun
Institution:1.School of Laboratory Medicine, Bengbu Medical College, Bengbu Anhui 2330302.State Key Laboratory of Radiation Medicine and Radiation Protection, Soochow University, Suzhou Jiangsu 2151233.School of Radiation Medicine and Protection, Medical College of Soochow University, Suzhou Jiangsu 2151234.Department of Nuclear Medicine, The First Affiliated Hospital of Bengbu Medical College, Bengbu Anhui 233004, China5.School of Clinical Medicine, Bengbu Medical College, Bengbu Anhui 233030
Abstract:ObjectiveTo analyze the risk factors influencing the excellent response(ER) in differentiated thyroid carcinoma(DTC) patients without distant metastasis after 131I therapy.MethodsOne hundred and sixty patients treated with 131I treatment were followed for 24 months, and the efficacy response of all cases after 3, 6, 12 and 24 months of treatment were evaluated.The clinicopathological differences of patients with different therapeutic stratification were analyzed using χ2 test, Fisher exact test and Mann Whitney U test, and the logistic regression analysis and ROC curve analysis were used to explore the factors affecting ER.ResultsCompared with the initial evaluation, the ER rate at the final evaluation significantly increased(P < 0.01).The proportion of patient with younger age, lower ps-Tg level, 131I treatment times < 3, 131I total dose < 500 mCi, low initial risk stratification and initial TNM stage Ⅰ-Ⅱ in ER group were higher those in non-ER(P < 0.05 to P < 0.01).The results of logistic multiple regression analysis showed the serum ps-Tg was a protective factor affecting end-stage ER(OR=0.942, P < 0.01).The areas under ROC curve of the relationship between ps-Tg and initial ER, and final ER were 0.884 and 0.762, respectively.The optimal critical values of predicting non-ER were 16.62 ng/mL and 46.37 ng/mL(P < 0.01).ConclusionsThe efficacy of 131I in the treatment of DTC patients without distant metastasis is significant.The serum ps-Tg is of great value in predicting the initial and final evaluation of curative effects.
Keywords:
本文献已被 万方数据 等数据库收录!
点击此处可从《蚌埠医学院学报》浏览原始摘要信息
点击此处可从《蚌埠医学院学报》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号